Economic Burden of Lyme Disease: Billions in Costs and Rising
The economic burden of Lyme disease is substantial, reaching billions of dollars annually in the United States. An estimated 240,000 to 440,000 individuals are diagnosed each year, with average treatment costs of approximately $3,000 per patient annually. :contentReference[oaicite:0]{index=0}
When persistent symptoms and ongoing care are included, total healthcare costs may reach $1.3 billion per year.
“Our study looks at the actual costs of treating patients in the year following their Lyme diagnosis,” explains Emily Adrion, MS. These costs include repeated medical visits and diagnostic testing for symptoms that have not resolved after initial treatment.
What Drives the Cost?
Much of the economic burden stems from patients who continue to experience symptoms after treatment.
Common persistent symptoms include:
- Fatigue
- Muscle and joint pain
- Cognitive impairment
These ongoing symptoms often require additional evaluations, testing, and follow-up care.
Even when the diagnosis is established, care does not end—costs continue to accumulate.
Persistent Symptoms Are Common
Research suggests that persistent symptoms may be more common than previously reported.
- 63% of treated patients had at least one PTLDS-related diagnosis
- This is 36 percentage points higher than individuals without Lyme disease
In contrast, CDC estimates suggest that only 10–20% of patients experience lingering symptoms.
This gap raises important questions about whether the true burden of illness is being underestimated.
Increased Healthcare Utilization
Patients with Lyme disease utilize significantly more healthcare resources:
- 5.5 times more likely to be diagnosed with debility and excessive fatigue
- 87% more physician visits within one year
- 71% more emergency room visits compared with matched controls
These increases reflect the ongoing complexity of managing persistent symptoms.
The True Cost May Be Higher
Earlier estimates suggest that Lyme disease may be even more costly than current figures indicate.
- Average annual cost per patient estimated at $16,199
- Total national cost estimated at $203 million based on reported cases
However, since actual case numbers may be at least ten times higher than reported, the true economic burden may approach $2 billion annually.
Most of these costs are indirect, including lost productivity, disability, and nonmedical expenses.
Comparison With Other Chronic Conditions
The economic burden of chronic Lyme disease exceeds that of several other chronic illnesses:
- $10,911 for fibromyalgia
- $10,716 for rheumatoid arthritis
- $13,094 for lupus
This highlights the significant and often underrecognized impact of Lyme disease on patients and society.
Why This Matters
Much of the ongoing cost reflects uncertainty in diagnosis and treatment.
Patients often undergo repeated testing, consultations, and retreatment due to persistent symptoms.
“Many people… are going back to the doctor complaining of persistent symptoms, getting multiple tests, and being retreated.”
Debate continues over how to define and treat these patients, whether described as PTLDS or chronic Lyme disease.
Regardless of terminology, the economic and clinical burden is clear.
Clinical Perspective
Lyme disease is not only a clinical challenge—it is a public health and economic issue.
Improving early diagnosis, refining treatment strategies, and addressing persistent symptoms are essential to reducing both patient suffering and societal costs.
Failure to recognize the full scope of Lyme disease may lead to continued underestimation of its impact.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
